Annovis Bio (ANVS) has issued an update.
Henry Hagopian has resigned as CFO of Annovis Bio to explore new opportunities, effective April 30, 2024. His departure is amicable, involving no disputes over financial practices. The CEO, Maria Maccecchini, steps in as interim CFO. Hagopian’s exit package includes two months’ salary, health premium reimbursements, vested stock options, and extended option exercise periods, contingent on adherence to a Separation Agreement.
For detailed information about ANVS stock, go to TipRanks’ Stock Analysis page.
